The erythrocyte osmotic resistance test as screening tool for cholesterol-related lysosomal storage diseases

被引:3
|
作者
Lopez de Frutos, Laura [1 ,2 ]
Cebolla, Jorge J. [1 ,3 ,4 ]
Irun, Pilar [1 ,3 ]
Koehler, Ralf [3 ,5 ]
Giraldo, Pilar [1 ,2 ,3 ]
机构
[1] Hosp Univ Miguel Servet, Inst Invest Sanitaria Aragon IIS Aragon, GIIS 012, Unidad Invest Traslac, Zaragoza 50009, Spain
[2] Fdn Estudio & Terapeut Enfermedad Gaucher & Otras, Zaragoza 50009, Spain
[3] CIBERER, U 752, Zaragoza 50009, Spain
[4] Univ Zaragoza, Dept Bioquim Biol Mol & Celular, Zaragoza 50009, Spain
[5] Fdn Agcy Aragonesn Invest & Desarrollo ARAID, Zaragoza 50009, Spain
关键词
Niemann Pick type C; Lysosomal acid lipase deficiency; Osmotic haemolysis; Cholesterol-related lysosomal diseases; Screening test; PLASMA CHITOTRIOSIDASE ACTIVITY; ACID LIPASE DEFICIENCY; OXIDATIVE STRESS; MARKED ELEVATION; GAUCHER-DISEASE; FATTY-ACIDS; 7-KETOCHOLESTEROL; PERFORMANCE; DIAGNOSIS; FRAGILITY;
D O I
10.1016/j.cca.2018.02.010
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Erythrocyte volume regulation and membrane elasticity are essential for adaptation to osmotic and mechanical stress, and life span. Here, we evaluated whether defective cholesterol trafficking caused by the rare lysosomal storages diseases (LSDs), Niemann-Pick type C (NPC) and Lysosomal acid lipase (LAL) deficiency (LALD) impairs these properties. Moreover, we tested whether measurements of cholesterol membrane content and osmotic resistance serve as a screening test for these LSDs. Methods: Patients were genotyped for mutations in NPC1, NPC2, or LIPA genes. We measured LSD plasma biomarkers and LAL activity. Red blood cells (RBC) membrane cholesterol content was evaluated in 73 subjects. Osmotic resistance tests (ORT) were conducted in 121 blood samples from LSD suspected patients and controls. Results: We did not find statistically significant differences between RBC cholesterol content between subjects and controls. However, the ORT, particularly at 0.49% (w/v) hypotonic sodium chloride solution, revealed a significant higher osmotic resistance in LSDs patients than in controls. We established a cut-off value of <= 51% of haemolysis with sensibility and specificity values of 80% and 70%, respectively. Conclusions: NPC and LALD do not alter cholesterol content in the RBC membrane but increase osmotic resistance. Therefore, ORT serves as screening test for the studied LSDs.
引用
收藏
页码:161 / 165
页数:5
相关论文
共 50 条
  • [21] Multiplex Mass Spectrometry for Enzymatic Activities Screening of Lysosomal Storage Diseases
    Jayaweera, Tanlya
    Lon, Laura Darie
    Petre, Brindusa-Alina
    Darie, Costel
    FASEB JOURNAL, 2022, 36
  • [22] Broad screening test for sphingolipid-storage diseases
    Chen, CS
    Patterson, MC
    Wheatley, CL
    O'Brien, JF
    Pagano, RE
    LANCET, 1999, 354 (9182): : 901 - 905
  • [23] IS CHOLESTEROL TEST STRIP A GOOD TOOL FOR CVD RISK SCREENING ?
    Mabille, S.
    Cambier, J. F.
    De Meester, A.
    Marcovitch, O.
    Descamps, O.
    ATHEROSCLEROSIS SUPPLEMENTS, 2010, 11 (02) : 67 - 67
  • [24] Mutation Frequency of Three Neurodegenerative Lysosomal Storage Diseases: From Screening to Treatment?
    Duarte, Ana Joana
    Ribeiro, Diogo
    Oliveira, Pedro
    Amaral, Olga
    ARCHIVES OF MEDICAL RESEARCH, 2017, 48 (03) : 263 - 269
  • [25] Patients' perspectives on newborn screening for later-onset lysosomal storage diseases
    Lisi, Emily C.
    Gillespie, Scott
    Laney, Dawn
    Ali, Nadia
    MOLECULAR GENETICS AND METABOLISM, 2016, 119 (1-2) : 109 - 114
  • [26] LRRK2 and RAB8A regulate cell death after lysosomal damage in macrophages through cholesterol-related pathways
    Tengberg, Josefine Fussing
    Russo, Francesco
    Benned-Jensen, Tau
    Nielsen, Jacob
    NEUROBIOLOGY OF DISEASE, 2024, 202
  • [27] Erythrocyte osmotic fragility test in dogs: preanalytical and analytical validation, frequent values, variations with diseases
    Baras-Cud, Y
    Guelfi, JF
    Concordet, D
    Dossin, O
    Braun, JP
    REVUE DE MEDECINE VETERINAIRE, 1998, 149 (8-9) : 867 - 874
  • [28] Application of Mass Spectrometry in Newborn Screening: About Both Small Molecular Diseases and Lysosomal Storage Diseases
    Hwu, Wuh-Liang
    Chien, Yin-Hsiu
    Lee, Ni-Chung
    Wang, Shiao-Fang
    Chiang, Shu-Chuan
    Hsu, Li-Wen
    CHEMICAL DIAGNOSTICS: FROM BENCH TO BEDSIDE, 2014, 336 : 177 - 196
  • [29] Methods for assessing neurodevelopment in lysosomal storage diseases and related disorders: a multidisciplinary perspective
    Martin, Holly R.
    Poe, Michele D.
    Reinhartsen, Debra
    Pretzel, Rebecca E.
    Roush, Jackson
    Rosenberg, Angela
    Dusing, Stacey C.
    Escolar, Maria L.
    ACTA PAEDIATRICA, 2008, 97 : 69 - 75
  • [30] The Importance of Assay Imprecision near the Screen Cutoff for Newborn Screening of Lysosomal Storage Diseases
    Robinson, Bruce H.
    Gelb, Michael H.
    INTERNATIONAL JOURNAL OF NEONATAL SCREENING, 2019, 5 (02)